Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Current Report on Form 8-K dated June 16, 2025. The filing discloses the entry into a material definitive agreement to secure future equity financing.
Key Financial Metrics and Transaction Details
- Commitment Amount: Up to $25.0 million in common stock.
- Counterparty: YA II PN, LTD. ("Yorkville").
- Term: 36 months from execution.
- Pricing Mechanism: 96% of the lowest daily Volume Weighted Average Price (VWAP) during a three-consecutive trading day period.
- Issuance Cap (Exchange Cap): Limited to 151,755 shares (19.99% of outstanding shares) unless shareholder approval is obtained or the average sale price exceeds $3.66 per share.
- Ownership Limit: Yorkville's obligation is capped if its beneficial ownership would exceed 9.99% of outstanding voting power.
- Fees:
- Structuring fee: $25,000 (paid).
- Commitment fee: 2.00% of the Commitment Amount ($500,000 total), payable in five equal quarterly installments.
Material Changes and Conditions
The filing represents a new financing facility rather than a change in historical financial performance. Key conditions for the agreement include:
- The filing and effectiveness of a Registration Statement with the SEC.
- Compliance with Nasdaq listing rules regarding the 19.99% issuance cap.
- Reliance on Section 4(a)(2) of the Securities Act for unregistered sales exemptions.
Outlook, Risks, and Management Commentary
The agreement provides Aptevo with the option, but not the obligation, to raise capital as needed over the next three years. The filing notes that the agreement is subject to standard limitations and that the Company may specify a minimum acceptable price per share for each advance. No specific guidance on future usage of the facility or operational outlook was provided in this report.
Investor Verification Checklist
- Verify the current number of outstanding shares to confirm the 151,755 share cap calculation.
- Monitor the status of the Registration Statement required for the sale of shares.
- Track the quarterly payment schedule for the $500,000 commitment fee.
- Review the full text of the Standby Equity Purchase Agreement (Exhibit 10.1) for specific limitations on "Advances."
- Assess the impact of the 96% VWAP pricing on potential dilution relative to current market prices.